Gastroenteropancreatic neuroendocrine tumor (gep-net)

Clinical trials for Gastroenteropancreatic neuroendocrine tumor (gep-net) explained in plain language.

Never miss a new study

Get alerted when new Gastroenteropancreatic neuroendocrine tumor (gep-net) trials appear

Sign up with your email to follow new studies for Gastroenteropancreatic neuroendocrine tumor (gep-net), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

Promising new combo therapy targets Hard-to-Treat gut tumors

Disease control Recruiting now

This study tests whether adding a radioactive drug (177Lu-DOTA-TATE) to standard therapy (octreotide) helps control advanced neuroendocrine tumors of the gut or pancreas better than standard therapy alone. About 240 newly diagnosed patients with slow-growing but high-burden tumor…

Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR (GEP-NET)

Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Sep 13, 2026 00:00 UTC

Gastroenteropancreatic neuroendocrine tumor (gep-net)

Get alerted when new Gastroenteropancreatic neuroendocrine tumor (gep-net) trials appear

Promising new combo therapy targets Hard-to-Treat gut tumors